Oxidative stress is an established dementia pathway, but it is unknown if the use of antioxidant supplements can prevent dementia.
1
A 2014 review 2 of clinical trials from 1984 to 2014 showed a focus on enrolling patients with mild to moderate dementia in many trials, with no real progress on identifying diseasemodifying treatments. As a result, there has been a shift in focus to clinical trials emphasizing the prevention of cognitive decline, especially through secondary prevention trials targeting high-risk groups 3, 4 and large trials that promote lifestyle changes to address modifiable risk factors for AD. 5, 6 The usual primary end points of these trials are cognitive decline or composites of biomarkers and cognitive measures. 7 The gold standard of prevention is disease incidence, but to our knowledge, few current trials have this as their primary end point because of the time required to observe reductions in disease incidence. Multiple mechanisms associated with disease onset and progression have been described, 8 and one key mechanism implicated in AD is oxidative stress, 9 which may be modifiable through diet and/or antioxidant supplements. 10 Antioxidant use as a potential treatment for cognitive impairment or dementia has been of interest for many years. The use of vitamin E has had mixed results in treatment trials; in patients with moderate dementia treated for 2 years, its use slowed disease progression, 11 but more recently, when used in an antioxidant cocktail, its use failed to improve cognition in patients with AD with mild to moderate dementia. 12 It also failed as a preventive agent for dementia progression in persons with mild cognitive impairment, 13 although early in the trial, its use did somewhat improve cognition. A review 14 of controlled trials and case-control studies on the use of selenium in arresting the progression of AD also yielded mixed results. Observational studies correlate cognitive decline with decreased plasma selenium over time. 15, 16 However, to our knowledge, nothing is known about long-term use of these supplements as preventive agents in asymptomatic individuals. This article reports the main results of the Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADViSE) primary prevention trial. The PREADViSE trial, the largest primary prevention trial in AD to date, began in 2002 as an ancillary trial within the Selenium and Vitamin E Cancer Prevention Trial (SELECT), a double-blind randomized clinical prostate cancer prevention trial. 17 When SELECT ended prematurely in 2009
owing to results of a futility analysis, the PREADViSE trial continued as a cohort study for a subset of its enrollees. 18 Extended follow-up over a 7-year period (blinded) allowed for case ascertainment, yielding a comparison of the study arms for effectiveness in preventing dementia. We present the results of this large primary prevention study of antioxidant supplements as a method to modify oxidative stress, one mechanism in the evolution of AD. 9 
Methods

Design
Study design, 19 participant recruitment, and the conversion of the trial into a cohort study 18 are described in earlier publications. Briefly, the parent study, SELECT, was designed as a double-blind, 4-arm randomized clinical trial (RCT) and initiated enrollment in 2001. 17 The primary aim of SELECT was to determine the effectiveness of antioxidant supplements vitamin E (400 IU The trial protocol can be found in the Supplement. The RCT was powered to detect a hazard rate of 0.60 with 80% power, assuming a targeted enrollment of 10 400 men; this was then lowered to a detectable hazard rate of 0.50 once the actual enrollment finished at 7540 men. Study eligibility required SELECT enrollment at a participating site as well as the absence of dementia, active neurologic and neuropsychiatric conditions that affect cognition, or a history of serious head injury (>30-minute loss of consciousness within the last 5 years prior to enrollment) and substance abuse. The RCT was scheduled to continue supplements until 2012, but in September 2008, the SELECT Data and Safety Monitoring Committee recommended that supplements be discontinued owing to lack of efficacy on prostate cancer incidence. Study sites closed over the next 2 years, during which time both the PREADViSE trial and SELECT transitioned into cohort studies. 18, 20 Participants were asked to continue in the cohort study, and 4271 of the original 7540 men (56.6%) enrolled in the PREADViSE trial consented to continue annual memory screenings, which were then conducted by telephone. All study activities were approved by the University of Kentucky Institutional Review Board and by the institutional review boards at each SELECT site. All participants provided written informed consent.
during follow-up) as well as a self-reported dementia diagnosis, use of a memory-enhancing prescription drug (eg, donepezil, rivastigmine, galantamine, or memantine), or cognitive score 1.5 SDs or more below expected performance yielded a dementia diagnosis. The diagnosis date was assigned to the earliest event.
Statistical Methods
Groups were compared using χ 2 statistics for categorical variables and 2-sample t tests or analyses of variance for intervallevel variables. Cox proportional hazards models were used in a modified intent-to-treat (mITT) analysis to compare hazard rates among the study arms. Hazard ratios (HRs) were adjusted for baseline age, black race, APOE ε4 carrier status (present or absent), college education, baseline MIS score, and the presence or absence of the following self-reported comorbidities at PREADViSE trial baseline: coronary artery bypass graft, congestive heart failure, diabetes, hypertension, stroke, sleep apnea, and memory change or problem. In this analysis, survival time represents the time from PREADViSE trial baseline to ascertainment of a case (event) or last cognitive assessment (right censored). All dropouts owing to death, personal withdrawals from the study, and administrative withdrawals (eg, SELECT sites not reconsenting men for the cohort study) were right censored. The proportional hazards assumption required by the Cox model was checked using martingale residuals and Schoenfeld residuals. The latter analysis indicated that proportionality was met for the indicators of the treatment arms and all covariates except for the indicators of baseline memory problems and baseline MIS score less than 7 or 8. A stratified analysis using the combination of these latter 2 variables yielded the same results for the effect of the treatment arms. Therefore, the original Cox model is reported here.
Missing APOE ε4 carrier status values (352 of 7338 participants [4.8%]) were imputed; a reanalysis limited to known APOE ε4 carriers yielded virtually the same results as those reported here. Three additional analyses were conducted. First, the observations were weighted by treatment compliance. This weight equaled the length of time the man could take the supplements (ie, time between enrollment and the date the supplements were stopped) multiplied by the proportion of visits at which the man was compliant with assigned supplement 1 (ie, vitamin E or placebo) or compliant with supplement 2 (ie, selenium or placebo), whichever was greater. Compliance information was based on returned pill counts. For example, suppose a randomly selected study participant had 3 years receiving treatment, and he was found to be 50% compliant with assigned treatment. The weight assigned to that man's record was 1.5 (3 years × 50% compliance, normed to make the sum of all weights equal the sample size for this analysis, given the 7289 men with compliance information). Second, the Cox models were refitted using only medical recordsbased dementia as the outcome (in other words, patients identified without medical records were right censored). Table 1 shows that the 3786 participants evaluated with at least 1 memory screen in the cohort study were similar to the complete PREADViSE trial enrollment, except possibly for less education at the college level or higher (52.2% vs 60%), fewer black participants (8.4% vs 10.0%), and fewer Hispanic participants (2.5% vs 6.9%). on the means and percentages, despite randomization occurring at SELECT baseline rather than PREADViSE trial enrollment, there were no perceivable differences between study arms in terms of medical history, APOE ε4 genotype, or initial MIS score. Incident dementia cases were defined as above. There were 325 of 7540 men (4.3%) with incident dementia in the study, and of these, 121 of 325 men (37.2%) provided medical records ( Table 3) . Unadjusted cumulative dementia incidence varied among the study arms; there were 71 men (4.0%) in the vitamin E arm, 78 men (4.2%) in the selenium arm, 85 men (4.6%) in the placebo arm, and 91 (5.0%) in the combination arm (Table 3) .
Results
To compare the hazard rates for dementia among the 4 study arms, mITT analysis based on a Cox proportional hazards model was fitted to the data. The mITT analysis excluded 201 participants who had only a baseline visit. Hence, the Cox model included 7338 men with at least 1 follow-up visit. None of the active study arms had a significantly lower adjusted hazard rate for incident dementia compared with the placebo arm; the vitamin E arm had an HR of 0.88 (95% CI, 0.64-1.20), while the selenium arm had an HR of 0.83 vs placebo (95% CI, 0.61-1.13) ( Table 4 ). The combined supplements arm was indistinguishable from the placebo arm and had an HR of 1.00 (95% CI, 0.74-1.35) (Figure) .
Because this was a truncated RCT (owing to the futility analysis for SELECT), the Cox model was refitted by weighting each man's survival time to dementia by the length of time that man was exposed (time receiving supplement) multiplied by the estimated proportion of this time that the man was compliant with the assigned treatment (ie, compliance). The weighted analysis showed results similar to the unweighted mITT analysis (Table 4) .
Additional sensitivity analyses were conducted. First, the analysis was restricted to the 3786 participants who volunteered 
Discussion
The PREADViSE trial was a double-blind RCT conducted as an ancillary study to a cancer prevention trial (SELECT), both of which evolved into observational cohort studies. This trial investigated whether the supplements vitamin E and selenium used alone or in combination would prevent new AD or dementia onset. The results showed that neither vitamin E nor selenium (with a mean [SD] time of supplement use of 5.4 [1.2] years) had a significant preventive effect on incidence. One possible explanation for the negative findings is that the trial met only 75% of its planned accrual; however, the results also show that the effect sizes observed for either supplement are likely much lower than the projected HR of 0.60. 19 Nevertheless, to our knowledge, this is the first large-scale primary prevention trial to investigate the association of antioxidant supplements with reducing dementia incidence. The PREADViSE trial is a member of the first generation of AD prevention trials, 27-30 all of which failed in their primary goal. One common reason for the failure of those trials was the low incidence of AD and dementia observed during follow-up. This was attributed partially to selection bias, since participants had higher levels of education than the general population and perhaps more cognitive reserve. Dementia incidence among PREADViSE trial participants was very low for several additional reasons. Case ascertainment could not use modern diagnostic procedures because those with suspected dementia did not, as a rule, visit dementia specialists for diagnosis. Instead, ascertainment relied on a consensus review of medical records derived from a variety of care professionals. Case ascertainment was also affected by continual staff turnover at study sites in the RCT component of the study, which was associated with a low cognitive screen failure rate (less than 1%). The failure rate increased substantially once centralized follow-up began. 18 The rationale for this trial was supported by results from the basic sciences as well as observational and prospective studies in humans suggesting that the use of antioxidants improved cognition and reduced dementia incidence. The studies preceding the trial focused more on the benefits of vitamin E because it was being evaluated in a number of therapeutic trials at that time, including a trial that studied its effect on the progression of mild cognitive impairment to dementia. 13 As in the mild cognitive impairment trial, vitamin E had no effect on dementia incidence in the asymptomatic cohort in the PREADViSE trial.
A 2014 review of studies on selenium 31 argues that selenium is vital for central nervous system function and that brain selenium levels are maintained at the expense of other tissues. A study 16 of 2000 rural Chinese individuals 64 years and older showed that participants in the lowest quintile of nail selenium levels had significantly lower scores on all instruments in the CERAD battery except for animal fluency. It is well known that high levels of selenium are toxic, inducing a severe selenosis by pro-oxidant action and glial activation, leading to neuronal death.
31
For the PREADViSE trial, dose decisions were made by a committee in the parent SELECT study. 32 The absence of biomarkers for target engagement of the supplements makes it difficult to translate basic science findings into prevention trials in a rigorous manner. Data monitoring in SELECT showed that selenium appeared to elevate levels of type 2 diabetes, although this elevated rate subsequently decreased with additional followup, and that vitamin E appeared to increase prostate cancer incidence. 17 The supplements had no effect on mortality, other cancers, cardiovascular events, nausea, fatigue, or nail changes. Selenium was associated with a significant increase in alopecia and grades 1 and 2 dermatitis 17 (Table 4 ).
Limitations
Our study had some limitations. The transitioning process cost the study about half of its participants for long-term followup; this was unavoidable because the study had to rely on SELECT sites to enroll the participants for the cohort study. Fortunately, Table 1 shows that the major cost was sample size (reduction in person-years of follow-up), as no new large selection biases were introduced. Aside from transitioning to a cohort study from an RCT, the PREADViSE trial had other limitations. Publicity about the negative effect of supplements may have affected the conduct of both the RCT and cohort study. The Future trials may benefit from electronic medical records. The reluctance to visit physicians prompted the introduction of the AD8 during the follow-up phase of the study, which could have induced bias because of the inability of participants or informants to distinguish anosognosia from dementia. This is a likely a small bias because examining those with medical records showed a high level of agreement with the AD8, as also evidenced in another study. 37 The reliability of telephone assessments vs in-clinic assessments used in the 2 phases of the study was less of an issue owing to high intraclass correlations, which ranged between 0.92 and 0.98. 38 In addition, the TICS-m has been shown to be a reliable discriminator between cognitively intact individuals and those with amnestic mild cognitive impairment.
39
Conclusions
The supplemental use of vitamin E and selenium did not forestall dementia and are not recommended as preventive agents. This conclusion is tempered by the underpowered study, inclusion of only men, a short supplement exposure time, dosage considerations, and methodologic limitations in relying on real-world reporting of incident cases.
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REVISION #1
The study referenced above has been revised to allow more flexibility for registration to PREADVISE in conjunction with SELECT randomization. Sections 5.1 (page 6), Section 7.2 (page 7) and Section 9.0 (page 9) have been revised to reflect the following:
"Participants who were randomized to SELECT prior to October 1, 2002 may be registered to PREADVISE: 1) at, or within 28 days following their first Six Month SELECT Visit, or 2) at, or within 28 days following their first Annual SELECT Visit. Participants who are randomized to SELECT on or after October 1, 2002, may be registered to PREADVISE only at, or within 28 days following their SELECT randomization." Sections 5.3 (page 6) and 7.2 (page 7) were revised to indicate that the applicable age requirement is "at this time of registration to PREADVISE" rather than "at the time of SELECT randomization".
Operations Office
Replacement pages are enclosed for pages 6, 7 and 9. Please insert them into your copy of the protocol. b.
To assess the combined and individual effects of selenium and vitamin E in the reduction of the incidence of other neurodegenerative diseases, including dementia with Lewy bodies, frontotemporal dementia (including Pick's disease), corticobasal degeneration, progressive supranuclear palsy, and vascular dementia.
c. Evaluate the sensitivity and specificity of the Memory Impairment Screen (MIS) relative to the Consortium to Establish a Registry in AD (CERAD) mental status measures (in a subsample of 500 participants).
d. Study the features of normal cognitive aging (in a subsample of 200 participants) and to assess the effect of selenium and vitamin E on this process.
e. Study the progression of AD and other neurodegenerative diseases in participants clinically diagnosed with AD or other dementia.
1.3
Tertiary Objective -To evaluate the association of apoliprotein E (APOE) ε 4 alleles and other potential biological molecular markers with the risk of Alzheimer's disease and other neurodegenerative diseases in this population.
BACKGROUND Past findings:
Normal aging is often accompanied by changes in physical and mental health. However, pathological aging involves a host of disorders. The most common, Alzheimer's disease (AD), currently afflicts roughly 4 to 6 million persons in the United States. It is estimated that up to 22 million persons will develop AD in the United States by the year 2025 if effective treatment or prevention are not found. Additionally, there will be an estimated 2 to 4 million related dementias such as dementia with Lewy bodies, frontotemporal dementia, and vascular dementia.
For this study, age-associated changes in memory will be monitored as a "sentinel system" for the development of dementia. These data are needed to better understand the incidence and prevalence of dementia over the age of 62 and how it may be influenced by antioxidant supplements. Current estimates from Caucasian populations suggest that roughly 11% of persons over the age of 65 have AD. However, epidemiological data show only a modest incidence for AD in Caucasian men aged 55 to 64 implying that it would not be cost effective to screen men younger than age 62 for AD. These same data show that AD incidence quickly rises in men after age 64. Some studies suggest that Hispanic groups and people of African descent may have a higher AD incidence estimated at 2 to 4 times that of Caucasian groups. Further, as dementia prevalence increases with age, some estimates for AD in persons over the age of 80 are as high as 48%.
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The primary neuropathological changes in the AD brain involve cell loss, accumulation of neurofibrillary tangles and senile plaques as well as the loss of neurotransmitters. Current therapy with anticholinesterase compounds (e.g., Aricept, Exelon, Reminyl, Cognex) and antioxidants (vitamin E) have provided modest symptomatic relief over the short term, at best. Therefore, prevention strategies may prove to be the most cost effective method for reducing the burden associated with dementia. Based on in vitro and in vivo studies, there is a good rationale for using antioxidant treatments in an effort to impede the development of dementia.
Over These data also suggest a gradient of risk such that persons with the ApoE ε 4/ε 4 genotype may develop AD at a significantly earlier age than ApoE ε 4/ε 3 heterozygotes, who in turn may develop dementia earlier than ApoE ε 3/ε 3 homozygotes. These data suggest that the ApoE ε 4 allele is an important risk factor that may account for about 40% of nonfamilial AD cases. The addition of the tertiary aim for this study provides the PREADVISE investigators the opportunity to evaluate not only APOE but other unknown, yet to be defined molecular markers that may be associated with AD or other dementia. Thus circumventing the need to amend the protocol in the future for the purposes of examining associations between molecular markers and AD. The sample for the ApoE genotype testing will come from stored blood specimens at the SELECT Biospecimen Storage Facility at NCI-Frederick, located in Frederick, MD.
Since men who are at risk for prostate cancer are also over the age of 50, this study represents a unique opportunity to assess the impact of the SELECT prevention strategy on the evolution of dementia, especially as the incidence and prevalence of dementia rises with age.
Oxidative Stress in Alzheimer's Disease: At present, no effective therapies are available for AD and it is highly desirable to develop preventive measures. Although the etiologies of AD are not known, a partial understanding of the cascade of pathophysiologic events involved in neuron degeneration has been achieved, some of which may have modifiable steps. Oxidative stress plays a major role in the pathogenesis of neuron degeneration in AD and probably other neurodegenerative diseases. Most investigators believe that prevention is the key to AD and that preventive measures should start early in life. A growing body of evidence indicates that increased oxidative stress, from free radical damage to cellular functions, is associated with neurodegenerative diseases. The evidence has been most clearly demonstrated for AD, where multiple studies show increased oxidation of brain lipids, proteins, carbohydrates and DNA.
Enhancement of brain levels of selenium (Se) might increase antioxidant defense mechanisms in AD by increasing brain glutathione peroxidase and glutathione concentrations and thioredoxin reductase levels. Increasing Se levels might also enhance the relationship between Se and vitamin E. The possibility exists that together they can be much more efficient as antioxidants. Organized trials of Se alone or in conjunction with vitamin E in individuals at risk for AD have not been carried out previously.
A double-blind, placebo-controlled, randomized multicenter trial of vitamin E and selegiline in 341 AD patients of moderate severity for two years revealed mild slowing of the progression of the disease in both groups. Vitamin E was superior to selegiline or combination therapy in delaying the time to the primary outcome (death, institutionalization, loss of ability to perform activities of daily living or severe dementia). (22) Importantly, no significant side effects were encountered in the dose of 2,000 units of vitamin E daily. A similar large trial of 2,000 IU of vitamin E daily in S0000A Page 5
Parkinson's with dementia patients revealed no improvement, but also showed no significant side effects. (15) Although the AD study showed that vitamin E slowed the progression of the disease slightly when given over a two-year period, additional studies are needed to establish the value of lower doses of vitamin E in the long-term management of AD.
In summary, it appears that the key to AD is prevention and that preventive measures should start early in life. There are compelling data that the brain in AD is under heightened oxidative stress. The PREADVISE study is aimed at reducing oxidative stress using antioxidant agents in the presymptomatic stage to delay or prevent the onset of the disease.
Inclusion of Minorities and Underserved/Uninsured
It is a standing policy of the Southwest Oncology Group to include eligible patients and/or participants of both sexes and all races and ethnicities in all Group clinical trials, except as restricted by specific disease site (e.g., prostate, gynecological). The proposed participant population for the full SELECT study (S0000) will consist of males, due to the specific disease site (prostate), and will include minority populations, including, but not limited to, AfricanAmericans, Hispanics, Asian-Americans, as well as medically underserved populations. As African-American males are at higher risk for the development of prostate cancer, an attempt will be made to over-recruit this population through specific recruitment and adherence strategies. Previous minority accrual in Southwest Oncology Group genitourinary and cancer control studies in 1998 and other relevant studies is shown below: 
ACCRUAL
DRUG INFORMATION
Drug information is not applicable to this study. This study will use the same agents as the main SELECT protocol (S0000). 
5.1
The potential PREADVISE participant must be a SELECT participant. Participants who were randomized to SELECT prior to October 1, 2002 may be registered to PREADVISE: 1) at, or within 28 days following their first Six Month SELECT Visit, or 2) at, or within 28 days following their first Annual SELECT Visit. Participants who are randomized to SELECT on or after October 1, 2002, may be registered to PREADVISE only at, or within 28 days following their SELECT randomization. Follow-up for PREADVISE will be at each subsequent Annual SELECT Visit.
5.2
A baseline Memory Impairment Screen (MIS) must be administered prior (within 30 days) to enrollment in PREADVISE and the participant must score greater than 4. Participants whose scores are 4 or less will not be registered to PREADVISE.
5.3
Participants must be age 62 or older at the time of registration to PREADVISE. Men of African or Hispanic descent must be 60 or older at the time of registration to PREADVISE.
5.4
The participant must not have any of the following neurological conditions based on selfreport (were told by a physician):
Alzheimer's disease, or any other form of dementia such as Pick's disease, dementia with Lewy bodies, frontotemporal dementia, vascular dementia, significant cognitive and motor impairment from a stroke or corticobasal degeneration.
Huntington's disease, epilepsy, Parkinson's disease, brain tumor, multiple sclerosis, manic-depressive disorder, or schizophrenia.
5.5
The participant must not have had a head injury with prolonged loss of consciousness (over 30 minutes) within the past five years.
5.6
The participant must not have had an alcohol or substance abuse diagnosis in the past 24 months.
5.7
The participant must not have had a diagnosis of depression or anxiety disorder in the past 4 months.
5.8
The participant must not currently use of any of the following medications: Aricept, Cognex, Exelon, Reminyl, or Hydergine.
5.9
The participant must not have blindness, deafness, language difficulties or any other disability that may prevent completion of the MIS.
5.10
Participants must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines before PREADVISE procedures are initiated.
5.11
At the time of participant registration, the treating institution's name and ID number must be provided to the Statistical Center in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered into the data base.
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STRATIFICATION FACTORS
Stratification factors are not applicable to this study.
TREATMENT PLAN
All participants will receive treatment as outlined in S0000.
Please refer all questions regarding the Memory Impairment Screen (MIS) or any procedures related to PREADVISE to Dr. William Markesbery or the PREADVISE staff at 866/846-1412.
Detailed procedures for the Baseline Visit and Annual Visits can be found in the PREADVISE Study Manual which is Appendix J of the SELECT Study Manual.
7.1
The MIS is a brief memory screening test that can easily be administered by the Study Site staff at the participating sites. Training for administering the MIS will be conducted through workshops during the semi-annual Southwest Oncology Group Meetings. Detailed instructions can also be found in the PREADVISE Study Manual. The scoring of the MIS (0-8) will be completed by the Study Site staff. The time required to administer the MIS is 5 to 10 minutes.
Registration Visit
PREADVISE registration activities are conducted in conjunction with the SELECT Initial and Randomization Visits to determine eligibility for PREADVISE. Participants who were randomized to SELECT prior to October 1, 2002 may be registered to PREADVISE: 1) at, or within 28 days following their first Six Month SELECT Visit, or 2) at, or within 28 days following their Annual SELECT Visit. These participants must meet the age requirement of 62 (60 if of African or Hispanic descent) at the time of registration to PREADVISE.
Prior to administration of any PREADVISE procedures, the potential participant will sign the PREADVISE informed consent. The participant will be asked to complete the Family History of Dementia (Form #310) and be evaluated for eligibility using the data on the Neurologic Medical History (Form #311). If the consented participant is potentially eligible he will then be given the Memory Impairment Screen (MIS). The MIS result must be greater than 4. Scores of 4 or lower on the MIS at the time of registration into PREADVISE will be exclusionary (possible prevalent case).
A modified Hachinski rating (risk of vascular dementia) will be completed by the PREADVISE Coordinating Center based on data from the Neurologic Medical History (Form #311) as well as additional information from physical exams, vital signs, other concurrent medications and laboratory data extracted from SELECT database.
Annual Visits
The annual visits for PREADVISE are concurrent with the SELECT Annual Visits and will include the administration of the MIS, and Neurological Medical Events (Form #313). In the event of a MIS score of 4 or less, an expanded mental status assessment with the CERAD tests (see Section 10.2) will be completed. If scores from the expanded evaluation are below cutoffs, a medical evaluation for dementia will be recommended to the participant and scheduled 4 to 6 weeks after the Annual Visit. Extension of this period may be granted, on a case-by-case basis, if discussed with and approved by the PREADVISE Investigators. The participant may withdraw from the study at any time for any reason.
7.5
The participant will be followed as described in the main SELECT protocol (S0000).
TOXICITIES TO BE MONITORED AND DOSAGE MODIFICATIONS
Dose modifications will be performed as outlined in Section 8.0 of the main SELECT protocol (S0000).
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10.1
The primary endpoint of this trial is the diagnosis of AD or other dementia at a moderate to severe level using National Institute of Neurological Disorders and Stroke/Alzheimer's Disease and Related Disorders Association and Diagnostic and Statistical Manual-IV (DSM-IV) criteria by a consensus conference (see Appendix Section 19.1). Diagnosis will be obtained using the three-stage process described below.
Alzheimer's Disease Diagnostic Process
Stage 1: Cognitive Screening Using the MIS: Because several thousand men will be annually screened for AD, the MIS is used as the first stage screen due to its brevity (5 minute) and reasonable sensitivity and specificity.
(1) A cutoff point of 4 (on an 8-point scale) will be used to stratify participants at this stage. All enrolled participants scoring above 4 on an Annual Visit MIS screening will return the following year for another MIS screening examination. A score of 4 or lower on an Annual MIS screening will indicate a need for the participant to proceed to the second stage CERAD battery of tests. These tests are necessary to evaluate for potential memory problems that were suggested by a low score on the MIS (See "Stage 2: Cognitive Screening Using the CERAD Tests" below). Each of these measures has been well standardized. Spanish/French versions are available and can be accessed from the SELECT workbench. (12, 24) The time required to complete this battery of tests is approximately 45 minutes and the site will be compensated for this time and for the submission of the forms to PREADVISE. Completed data forms from the CERAD evaluation will be faxed to the PREADVISE Coordinating Center where scoring of CERAD measures will be completed. A participant who scores 2 standard deviations below the normal mean on the MMSE or 2 standard deviations below the mean on at least one memory test and on one other test will meet the criteria for cognitive impairment or change in cognition and will proceed to Stage 3 (medical dementia evaluation and consensus conference) of the dementia screening process (see Medical Evaluation Section below). If a participant passes the CERAD screening, he will be reevaluated (starting with Stage 1: MIS) at the next annual SELECT visit.
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The CERAD tests are supplemented with the Geriatric Depression Scale to screen for depressive symptoms. (25) A score of 12 or higher on the GDS alone will result in a referral recommendation for an evaluation for depression.
Because the CERAD battery of tests is for those participants who score 4 or lower on the MIS during an Annual Visit, these tests will not be needed until the first registered participants make their first annual return visit. The Study Site staff at the participating sites will be trained by PREADVISE staff to administer the CERAD tests through workshops during the semi-annual Southwest Oncology Group Meetings, beginning in October 2002. CERAD testing of the validation and normal aging subgroups will be done at SELECT sites that are associated with Alzheimer's Disease Centers (ADCs). Personnel at these ADCs are already familiar with administering these tests. The CERAD forms will then be forwarded to the PREADVISE Coordinating Center in Lexington, KY where they will be scored, and the scores interpreted by qualified PREADVISE staff.
If the CERAD battery of tests indicate a memory problem, the SELECT and PREADVISE clinicians will encourage the participant to undergo a medical evaluation to rule out medical causes for his memory problems. If the site is near, or associated with, an ADC, we would suggest that the participant have the medical evaluation performed by the professionals at the ADC. For example, the ADC at the Sanders-Brown Center on Aging at the University of Kentucky will be available to perform dementia evaluations for sites located in Lexington, Louisville, and Ashland, KY; Cincinnati, OH; Johnson City and Nashville, TN; and Charleston, Clarksburg and Morgantown, WV. However, the participant is free to use his physician and facility of choice.
PREADVISE receives no funding to provide medical services, so as with any medical needs, the participant will need to rely on Medicare or other insurance to cover the costs of medical tests and procedures associated with a medical or depression evaluation. Based on incident cases identified in the first 3 years of the study, we may apply for supplemental funding to assist uninsured persons with these evaluations. However, given that the majority of participants will be over the age of 65, Medicare coverage may apply to the majority of cases.
If at any return visit the participant self-reports that he has been diagnosed with any form of dementia or that he is taking medications for the treatment of AD (donepezil, rivastigmine, galantamine), he will be administered the CERAD tests to verify the dementia diagnosis, or verify that he has memory problems. Medical records will be requested from the prescribing physician for consensus conference review by the PREADVISE clinicians. If the evaluation resulting in the prescription of AD medications is considered inconclusive or incomplete or he does poorly on the CERAD tests, he will be encouraged to undergo a medical evaluation to rule out metabolic causes for his memory problems.
Stage 3: Medical Evaluation for AD:
For participants who meet criteria for cognitive impairment or change in cognition at any assessment, a clinical evaluation will be completed following completion of the second PREADVISE consent form. This evaluation will incorporate a review of medical and family history, general neurological and physical examinations, brain imaging study (CT or MRI), and standard laboratory evaluation of blood (complete blood count, vitamin B12 and folate levels, thyroid function studies, rapid plasma regain, blood metabolic screen to include electrolytes, glucose, calcium, phosphorous, liver function studies, renal function studies, and total protein). This evaluation will be coordinated by PREADVISE Coordinating Center staff working with the participant's Study Site staff, private physician, or a dementia specialist (neurologist, geriatrician, neuropsychiatrist) at the SELECT Study Site. Data from this evaluation will be forwarded to the PREADVISE Coordinating Center for review. If AD or another dementia is diagnosed, the participant will be re-evaluated with the CERAD measures on an annual basis until the participant is no longer able to comply with the PREADVISE S0000A Page 12 study procedures. These data will provide added clinical information of disease progression that will solidify the clinical dementia diagnosis. If dementia is not diagnosed, the participant will be followed with the proposed screening methods, starting with the MIS at the next SELECT Annual Visit.
Consensus Review for the Diagnosis of Dementia
Following the medical evaluation for dementia, a consensus group will review data at the University of Kentucky Alzheimer's Disease Research Center. This group is composed of three neurologists and two neuropsychologists with over 60 years of combined experience with clinical dementia assessment. The case will be presented to the group based on the evaluation that was completed by the local physician. These data will include the review of history, laboratory findings, physical and neurological examinations, MRI or CT scans, and mental status data. The DSM-IV criteria for diagnosis of dementia of the Alzheimer's type will be used. After the case has been reviewed, the group will generate a diagnostic summary. This summary will list the diagnosis(es), any need for additional data, and the degree of agreement between the clinicians. These data, in the form of a written summary, will be provided to the SELECT Study Site and the physician who completed the medical evaluation of the participant.
The diagnosis of other dementing disorders also will be determined in the Consensus Review Conference. For the diagnosis of dementia with Lewy bodies (DLB), the criteria of the Consortium on DLB International Workshop will be used. The MIS is a relatively new screening tool. There is a need to more carefully determine the sensitivity and specificity of the MIS in a population-based sample. For this purpose, a validation group of 500 men who pass the MIS screening will be evaluated at a few SELECT sites affiliated with ADCs. This validation will occur in the first two years using the CERAD. This will allow us to compare their performance to those individuals who "failed" the MIS and CERAD tests for the determination of sensitivity and specificity of the screening approach. This is a one-time assessment.
Age is the greatest risk for AD. Certain mental functions have been reported in retrospective studies to predict a diagnosis of dementia. This trial therefore represents an excellent opportunity to evaluate age-associated changes in cognition. Therefore, 200 of the 500 men from the validation sample will be asked to complete the CERAD tests in each year of the project. These results will then be compared to those who receive the diagnosis of AD during the course of the project. In these 200 individuals, the mental status battery (CERAD) will be supplemented by these five other brief tests (20 minutes) that have been suggested as predictors of dementia:
Digit Symbol Substitution, Trailmaking, Controlled Oral Word Association (COWA-verbal fluency), and Ruff 2&7 Test of Selective Attention National Adult Reading Test (NART) These tests will be administered and scored in the same manner as specified for CERAD (see above). These additional tests were selected on the basis that they provide an assessment of "usual" aging changes in cognition or processing speed. The Digit Symbol Substitution has also been reported to be a predictor of the evolution to dementia as well as overall memory performance. (3, 21) They also provide the most economical "paper and pencil" method for evaluating mental processing speed.
This evaluation of "usual" age-associated change, and the possible impact of APOE alleles and treatment on cognition, will involve those participants who were selected to complete the CERAD battery of tests after "passing" the initial MIS screening. Analyses will focus on the impact of the SELECT supplements on normal aging declines in these mental skills. These exploratory analyses will take place in Year 3 of the project, but data will continue to be collected through Year 5. If reliable changes, associations with cognition, or differences in change due to treatment arms emerge, we will apply for a supplement to this study to evaluate processing speed in more detail.
Secondary Endpoints
Diagnosis of other forms of dementia will be a consequence of the three stage screening process described above.
STATISTICAL CONSIDERATIONS
This trial will screen for AD among the subset of men aged 62 years or older (60 if of African descent or Hispanic) who are randomized to SELECT at participating Study Sites and who are cognitively intact at the time of randomization. It will then test the main hypothesis: use of both vitamin E and selenium will reduce the incidence of AD when compared to placebo (use of neither Study Supplement) among age cohorts for which the AD incidence curve is beginning to rise.
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We use a very conservative power calculation to show that a 40% reduction in the relative risk for AD is detectable with 80% power in this trial.
This detectable difference is estimated using the following assumptions explained in more detail below. Adjustments for participant drop-outs, drop-in, adherence rates, mortality and loss to follow-up have been made and are the same as those for SELECT. AD incidence rates for men are interpolated from midpoint to midpoint of five-year age groups (see Table 1 ) based on the expected distribution for the participants on study. Finally, a two-tailed test of significance at the 0.05 level is assumed. Under these assumptions the detectable relative risk is 0.60 for 80% power (0.55 for 90% power).
Based on scientific evidence (see Section 2.0, Background) and the fact that the Study Supplements are being administered very early in the incidence curve for this disease, it is not unreasonable to assume that the combined drugs will reduce the relative risk for AD by 40% or higher. This is a conservative calculation of a detectable difference for the following reasons: a) it relies on a two-tail test of significance when the main intent of the trial is clearly one sided (reduce incidence), and b) it is based on reliable but very conservative incidence figures for the disease.
Secondary Comparisons:
It is of interest to test the significance of the main effect of vitamin E (both vitamin E arms versus both vitamin E placebo arms) or the main effect of Se (both Se arms versus both Se placebo arms). Repeating the calculations above with double the sample size for testing a main effect, the proposed trial has 80% power to detect a relative risk of 0.69. The combination of vitamin E and Se has not been used together in trials of significant size populations. In addition, data are needed on the effects of low doses of vitamin E and Se over long periods (7 -12 years) in relation to the potential of preventing Alzheimer's Disease.
Number of Participants:
The number of men available for testing this contrast was estimated using the randomization data from SELECT as of February 14, 2002 . At that time 8,035 men were randomized to SELECT. The race and age-eligible distribution (60 for men of Hispanic or African descent, 62 for other races) is presented in the table below. Using a weighted averaged based on the race and age distribution, and a total accrual to SELECT of 32,400, it is estimated that approximately 17,600 men will be race/age eligible for PREADVISE. If we assume that 40% of the potentially eligible do not participate in PREADVISE either because it is not implemented at a Study Site or because of individual participant refusals, there will be approximately 10,560 men enrolled in PREADVISE.
AD Incidence Rate:
The incidence rates used in the power calculations are based on data for men only and are taken from the publication by Rocca, et al. (17) These rates are listed in Table 3 . Notice that these rates are comparable to the rates for both sexes combined available from a large number of incidence studies, provided the diagnosis of the disease is at a moderate or more severe level. (4, 6, 7, 18) These rates are conservative since they are derived from data on white men only, while a significant portion of the men recruited to the SELECT trial are expected to be of African descent or Hispanic who may have higher incidence rates. The incidence rates for older age cohorts are also needed because the surviving men will enter these age cohorts as the study progresses.
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Page 15 Hazard depends on adherence, a time dependent covariate. It is quantified by the medication rate defined as the percent of full active drug taken by men in a specified arm. Power calculations assume that adherence rates for men on active drug declines from 100% at randomization to 51% at the end of twelve years. Estimates are based on prior experience in the PCPT trial with extrapolations from Year 4 of that trial to Year 12.
Drop-in Rate:
The drop in rate for placebo subjects to active medication is assumed to be 10% over the 12 years of study.
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Death and Loss to Follow-up:
Adjustments for mortality were obtained by using the Life Tables for Males in the United States.  (13, see Table 2 ) The lost to follow-up rate is estimated to be 0.5% per year. 
Data Analysis Plan:
All data analyses will be the same as those conducted in the SELECT protocol. Five interim analyses are planned, occurring 5, 7, 9, 10, and 11 years after the first participant is registered. Additional reports on the incident Alzheimer's disease cases without reference to treatment arm will be made in Years 3 and 4 (also for competing renewal of the grant) to the SELECT DSMC and the External Advisory Committee of PREADVISE (comprised of four experts in AD epidemiology). This committee will meet annually with PREADVISE investigators to review study progress.
The five interim analyses will test the main contrast of interest (a relative risk of 0.6) at the .0005 level using an extension of the log rank test that allows for testing a relative risk not equal to one. Since SELECT has its own Data and Safety Monitoring Committee it is possible that one of the arms could be closed by this time for reasons not connected to this study.
The final analysis will be completed within six months of the end of the trial. At this point, 294 -329 AD incident cases will have been accrued depending on the magnitude of the reduction in incidence due to both vitamin E and Se. The log rank test will be used for each comparison of interest: main contrast of interest (compare the vitamin E plus Se arm with the double placebo arm) as well as the secondary contrasts (main effects of vitamin E and Se). Any other endpoints or contrasts of interest will be conducted at a 0.01 level of significance. The latter includes all forms of dementia, and overall mortality. Covariates such as APOE status and comorbid conditions will be included in the analysis to adjust for potential imbalances among the four arms. In addition, since a subsample of men passing the initial screen will also take the second stage screen, it will be possible to determine the robustness of the results using analyses suitable for longitudinal dementia studies with two-phase sampling designs. These analyses include an inverse probability weighting analysis, a full maximum likelihood analysis, and a mean score imputation analysis. (2) A recent selection model procedure of Gao, et al., will be also used to estimate the effect of non-ignorable missing data (due to deaths) on the estimation of incidence of AD and the comparison of the treatments. (5)
DISCIPLINE REVIEW
Discipline review criteria are included in Section 12.0 of the main SELECT protocol (S0000).
REGISTRATION GUIDELINES
Registration procedures are specified in the SELECT Study Manual.
DATA SUBMISSION SCHEDULE
Detailed data completion and submission procedures and schedule are found in the SELECT Study Manual.
SPECIAL INSTRUCTIONS
Special instructions are included in Section 15.0 of the main SELECT protocol (S0000).
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ETHICAL AND REGULATORY CONSIDERATIONS
The following must be observed to comply with Food and Drug Administration regulations for the conduct and monitoring of clinical investigations; they also represent sound research practice:
Informed Consent 
Drug Accountability
For each investigational drug supplied for a study, drug disposition (drug receipt, dispensing, transfer or return) shall be maintained on the NCI Investigational Drug Accountability Record. Drug supplies must be kept in a secure, limited access storage area under the recommended storage conditions. During the course of the study, the following information must be noted on the Drug Accountability Record; the ID # and initials of the subject to whom drug is dispensed, the date(s) and quantity of drug dispensed to the subject, and the date(s) and quantity of drug returned to the NCI or transferred to another NCI-approved protocol. These Drug Accountability Records must be readily available for inspection and are open to FDA or NCI inspection at any time.
Adverse Experiences
Any adverse experience, if deemed drug related, must be reported to the Operations Office Adverse Drug Reaction (ADR) representative (210/677-8808), who will obtain information on the ADR. Depending on the nature of the reaction and whether it was caused by an investigational or commercial agent, the ADR representative will advise whether the report to the NCI should be phoned in, written in, or both. See guidelines in the main SELECT protocol (S0000). On Phase II and III studies, all deaths considered drug-related must be reported immediately to the ADR representative. On double-blinded studies, if the investigator must know what treatment the subject received to make therapeutic decisions, the code for that particular subject can be broken by telephoning the Statistical Center.
All adverse experiences must also be reported to the Institutional Review Board within 10 days and documentation of this report sent to the Operations Office.
All adverse experiences must also be recorded in the appropriate section of the case report form. The report should include, whenever possible, the investigator's written medical judgment as to relationship of the adverse experience to study medication(s) (i.e., "probable", "possible" or "unrelated").
Monitoring
This study will be monitored by the Clinical Data Update System (CDUS) Version 2.0. Cumulative CDUS data will be submitted quarterly to CTEP by electronic means. Reports are due January 31, April 30, July 31 and October 31.
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This model informed consent form has been reviewed by the DCP/NCI and is the official consent document for this study. Local IRB changes to this document are allowed. (Institutions should attempt to use sections of this document which are in bold type in their entirety.) Editorial changes to these sections may be made as long as they do not change information or intent. If the institutional IRB insists on making deletions or more substantive modifications to the risks or alternatives sections, they may be justified in writing by the investigator and approved by the IRB. Under these circumstances, the revised language, justification and a copy of the IRB minutes must be forwarded to the Southwest Oncology Group Operations Office for approval before a participant may be registered to this study.
For IRB use only, not to be included in participant information. This research is being done to see how safe and effective vitamin E and selenium may be in preventing AD and other brain illnesses. These illnesses are more common in people over the age of 60 to 65.
HOWMANY PEOPLE WILL TAKE PART IN THE STUDY?
Participating in this study is your choice. About 10,000 men will take part in this study.
WHAT IS INVOLVED IN THE STUDY?
Each visit for PREADVISE will involve a short 5-minute exam of your memory, and questions about your medical history. If you agree to be in this study, your memory will be checked once each year. The 5-minute memory check will involve learning and remembering a short list of words. If the memory check suggests that you have memory changes, you will be asked to take a longer memory and thinking test. This may take an extra 45 to 60 minutes. It will involve a longer word list for you to learn and remember, naming pictures and drawing shapes. You will be asked to answer questions to check your language, word use and other skills as well as your mood.
If this second exam also suggests memory changes, you will be asked to see your family doctor, or a doctor identified by the SELECT or PREADVISE doctors, to complete a medical exam to find the possible causes of this memory change. This medical exam will be coordinated with you by the SELECT and PREADVISE staff. After the medical exam, one of the PREADVISE doctors will call you.
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They will talk with you and with a person who knows your day-to-day activities. If the second exam or doctor visit does not suggest memory and thinking changes, your memory will continue to be screened using the 5-minute check at the next yearly study visit.
If you are asked to complete a medical exam for memory changes, you will be given another consent form at that time. This will allow the results of the medical exam to be sent to the PREADVISE doctors for their review to help with diagnosis.
To check on the accuracy of the screening memory test, a smaller group of men (about 500) will be asked to complete the 45-minute exam, even though the memory screening did not suggest memory changes. This request will be determined by chance (such as a coin flip). If you agree, you will then be asked to continue to take both the screening and 45-minute memory and thinking tests each year. The results of these memory checks will not affect your participation in SELECT.
WHAT ELSE MIGHT YOU BE ASKED TO DO?
You may also be asked to be part of a group of 200 of these 500 men who will be asked to volunteer to continue to take both the 5-minute memory screening and the longer set of memory and thinking tests each year, plus five additional brief tests. This may take an additional 45 to 60 minutes during each Annual Visit. It involves a longer word list for you to learn and remember, naming pictures, drawing shapes, and questions to check your language, vocabulary, awareness skills, and mood. This request will be determined by chance (such as a coin flip). The results of these memory checks will not affect your participation in SELECT.
The results of the memory checks will not be given to you. If you do have a medical workup for memory changes, this information will be given to your doctor after your medical workup is completed.
At the start of the SELECT study you may have allowed a blood sample to be collected for future testing. The confidentiality and risk information related to this activity have been explained in the main SELECT consent form. This blood sample was stored by SELECT. For the PREADVISE study, part of this sample may be tested for a genetic risk factor associated with Alzheimer's disease, called Apolipoprotein E (ApoE). The results of this test will be used for research purposes only and you will not be told the results of this test. The ApoE information will be used to compare changes over time that might be associated with ApoE status. Even if you did not give a blood sample or did not consent to storage and testing of your blood sample, you may still participate in PREADVISE.
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HOWLONG WILL I BE IN THE STUDY?
The research exams will be done at the clinic where you are taking part in SELECT. There will be one study visit for each year that you are in SELECT (7 to 12 visits). These PREADVISE visits will take place during SELECT visits.
WHAT ARE THE RISKS OF THE STUDY?
Memory and thinking tests present practically no risk. The potential risks are small. You may have tiredness or fatigue from the testing. If you have any discomfort, you are free to stop at any time.
If you develop problems with memory and thinking during this study, you can choose medical testing and treatment through your family doctor, a specialist of your choice, or a specialist identified by the SELECT and PREADVISE doctors. The finding of any problems in memory and thinking will be made by the PREADVISE doctors' review of your study and medical records. If they think that there has been a change based on the memory and thinking tests used in this study, they and the SELECT doctors will tell you about your options for a medical workup. This may result in feelings of stress and anxiety about your health until the medical checkup is completed.
For more information about risks and side effects, ask the researcher or contact .
ARE THERE BENEFITS TO TAKING PART IN THE STUDY?
There is no guarantee that you will get any personal benefit from taking part in this study. However, it may be possible that the early detection of memory changes can lead to early diagnosis and treatment. You may also decrease your risk of getting AD, if the supplements are effective and you are taking them as part of SELECT. The findings of this study may also help in our understanding of Alzheimer's disease and may help other people with this disease in the future.
WHAT OTHER OPTIONS ARE THERE?
If you choose not to take part in PREADVISE, but remain in SELECT, you have these other options:
Some vitamin companies are selling other nutrients as supplements for memory. You may buy these supplements at your own expense without being in PREADVISE. However, the supplements must not contain vitamin E or selenium if you are in SELECT.
You can also have memory checkups by your family doctor. All of the checkups on this study may be available at this center or at other locations. Please talk to your regular doctor about these and other options.
WHAT ABOUT CONFIDENTIALITY?
Efforts will be made to keep your personal information confidential. We cannot guarantee absolute confidentiality. Your personal information may be disclosed if required by law.
Organizations that may inspect and/or copy your research records for quality assurance and data analysis include groups such as: the National Cancer Institute, the Sanders-Brown Center on Aging at the University of Kentucky, the Food and Drug Administration, the National Institute on Aging; the makers of vitamin E, selenium and placebo pills for the study, and the Southwest Oncology Group.
If we publish the information we learn from this study in a medical journal, you will not be identified by name or in any other way.
WHAT ARE THE COSTS?
Taking part in this study may lead to added costs to you or your insurance. Added costs may be due to finding AD or other diseases that cause memory loss at your examination. For example, your doctor may suggest a medical workup if you have an abnormal memory exam. These costs are discussed further below. Please ask your nurse or doctor about any expected added costs.
In the case of injury or illness resulting from this study, emergency medical treatment is available but will be provided at the usual charge. No funds/funds have been set aside to compensate you in the event of injury. (local institutions must choose the option that best fits the hospital's situation)
You or your insurance company will be charged for continuing medical care and/or hospitalization.
You will receive no payment for taking part in this study.
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WHAT ARE MY RIGHTS AS A PARTICIPANT?
Taking part in this study is voluntary. You may choose not to take part or may leave the study at any time. You may decline or stop taking part in PREADVISE without any effect on your participation in SELECT. Leaving the study will not result in any penalty or loss of benefits to which you are entitled. You can stop participating at any time. However, if you decide to stop participating in the study, we encourage you to talk to the researcher and your regular doctor first.
A Data Safety and Monitoring Board, an independent group of experts, will be reviewing the data from this research throughout the study. We will tell you about important new information from this or other studies that may affect your health, welfare, or willingness to stay in this study.
WHOM DO I CALL IF I HAVE QUESTIONS OR PROBLEMS?
The This is a clinical trial (a type of research study). Clinical trials include only people who choose to take part. Please take your time to make your decision. Discuss it with your family and friends.
You are being asked to take part in this research study because you are taking part in PREADVISE. PREADVISE is a study that looks at the use of vitamin E and selenium for preventing Alzheimer's disease and other memory diseases.
WHY IS THIS STUDY BEING DONE?
As part of PREADVISE, you have been having regular memory checkups. At this time, these memory checkups suggest that you may be having memory changes. Therefore, you are being asked to have a medical workup. Your doctor or a specialist that you can choose with help from the SELECT and PREADVISE doctors can do this workup to see if the memory change suggested by the checkup is related to a medical condition. The results of this testing will be used for medical diagnosis as well as for the PREADVISE research project.
HOWMANY PEOPLE WILL TAKE PART IN THE STUDY?
Participating in this study is your choice. If you volunteer to take part in this study, we think you will be one of about 300 to 500 men who may need this testing during their participation in PREADVISE.
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WHAT IS INVOLVED IN THE STUDY?
The medical evaluation for possible causes of memory problems will take place in your doctor's office. This will take about an hour of your time. Your doctor also will order a brain scan (computerized tomography (CT) or magnetic resonance imaging (MRI)) that may take up to 30 minutes. The total amount of time you will be asked to spend for this medical workup is about one to two hours.
This medical examination will involve a review by your doctor of your medical history, medicines, a physical and neurological exam, and blood and urine tests. If you agree to this part of the study, your medical test results will also be sent to the PREADVISE doctors for their review of possible causes of memory change.
If the information from this medical examination or doctor visit does not suggest a medical cause for memory changes, your memory will continue to be screened using the 5-minute check at the next yearly SELECT study visit. If a diagnosis of a dementia results from this medical examination, you will be asked to continue to take both the screening and 45-minute memory and thinking tests each year that you stay in PREADVISE and SELECT.
WHAT ARE THE RISKS OF THE STUDY?
Medical evaluations for possible causes of memory changes present practically no risk. The potential risks or discomforts are small. You may experience tiredness or fatigue from the evaluation. A Magnetic Resonance Imaging (MRI scan) may cause possible anxiety due to the loud banging made by the machine and the confined space of the testing area. People with pacemakers, aneurysm clips, artificial heart valves, ear implants, or metal/foreign objects in their eyes are not permitted to undergo an MRI, but may have a Computed Tomography (CT scan). A CT scan involves exposure to a small amount of radiation. The amount of exposure is less then 1,000 millirems. (An individual living in a city receives about 100 millirems per year). Risks associated with the drawing of blood include soreness, bruising, infection, bleeding, pain, and lightheadedness or fainting. In total, less than three tablespoons of blood will be taken, and your body will quickly make up for this loss.
There is also a risk that the medical exams will not be able to find a cause for your memory and thinking changes. However, if the cause is Alzheimer's Disease, medical diagnosis is correct 95 out of 100 times (95%) with this type of exam.
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ARE THERE BENEFITS TO TAKING PART IN THE STUDY?
There is no guarantee that you will get any personal benefit from participating in this part in this study. However, it may be possible that the early diagnosis of medical conditions that cause memory change can lead to effective early treatment for your condition.
WHAT OTHER OPTIONS ARE THERE?
You may choose not to have memory checkups at all. You can have memory checkups by your family doctor. All of the checkups on this study may be available at this center or at other locations. Please talk to your regular doctor about these and other options.
Efforts will be made to keep your personal information confidential. We cannot guarantee absolute confidentiality. Only your doctor and the PREADVISE and SELECT doctors will see the results of your medical examination. Your personal information may be disclosed if required by law.
Organizations that may inspect and/or copy your research records for quality assurance and data analysis include groups such as: the National Cancer Institute, the Sanders-Brown Center on Aging at the University of Kentucky, the Food and Drug Administration, the National Institute on Aging; the makers of vitamin E, selenium and placebo pills for the study and the Southwest Oncology Group.
Taking part in the medical examination for causes of memory change will lead to added costs to you or your insurance. Added costs may result from blood studies, urine studies, brain scans, and doctor examinations needed to determine a cause for your memory loss. For example, your doctor may suggest other medical tests if you have an abnormal blood test. Please ask your nurse or doctor about any expected added costs.
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WHAT ARE MY RIGHTS AS A PARTICIPANT?
Taking part in this study is voluntary. You may choose not to take part or may leave the study at any time. Leaving the study will not result in any penalty or loss of benefits to which you are entitled. You can stop participating at any time. However, if you decide to stop participating in the study, we encourage you to talk to the researcher and your regular doctor first.
WHOM DO I CALL IF I HAVE QUESTIONS OR PROBLEMS?
The persons in charge of this study are Drs. William Markesbery, Frederick Schmitt and Richard Kryscio of the Sanders-Brown Center on Aging at the University of Kentucky.
For questions about the study or a research-related injury, contact the researcher NAME(S ) at TELEPHONE NUMBER .
For questions about your rights as a research participant, contact the NAME OF CENTER Institutional Review Board (which is a group of people who review the research to protect your rights) at 
